Abbott Laboratories
Close on Nov 2, 2026Market cap $190.62BP/E 35.4Yield 2.18%
Abbott Laboratories Rapid and Molecular Diagnostics Division U.S. by Quarter
Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) U.S. — Organic / Comparable Sales Growth (%) (%)
Abbott Laboratories Rapid and Molecular Diagnostics Division U.S.: 1.1% in Q3 2026.
Where the Q3 2026 figure comes from
“|| Sales 3Q26 ($ in millions) | Total | Core Laboratory | Cancer Diagnostics | Rapid/Molecular Diagnostics || U.S. | 8.4 | 6.3 | 13.9 | 1.1”
Source: SEC Filing (0001628280-26-066601) ↗
Reported in Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) U.S. — Organic / Comparable Sales Growth (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 1.1% | – | SEC Filing (0001628280-26-066601) ↗ |
| Q2 2026 | Jun 30, 2026 | -14.5% | – | SEC Filing (0001628280-26-048377) ↗ |
| Q1 2026 | Mar 31, 2026 | -13.8% | – | SEC Filing (0001628280-26-025365) ↗ |
Cite this data
StockData. (2026). Abbott Laboratories Rapid and Molecular Diagnostics Division U.S. (%), quarterly Q1 2026–Q3 2026 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/dx-rm-yoy-org-us
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.